What is the risk of recurrent thrombosis among patients with antiphospholipid syndrome who receive DOACs?
Observational data suggest a high risk of recurrent thrombosis among patients with antiphospholipid syndrome who receive DOACs.618 Until other ongoing trials such as ASTRO-APS (Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid clarify whether the increased risk of thrombosis with DOACs is a class effect versus an individual drug effect, we do not recommend the use of DOACs in general and, specifically, rivaroxa- ban for antiphospholipid syndrome.